Tirzepatide Retinopathy Risk Not Increased in Type 2 Diabetes Study vs dulaglutide
A SURPASS-CVOT retina substudy found no increased diabetic retinopathy progression with tirzepatide compared with dulaglutide over 36 months.
Tirzepatide produced larger blood sugar reductions than dulaglutide in high-risk adults with type 2 diabetes, but it did not increase diabetic retinopathy development or progression in a 36-month retinal substudy. The findings offer reassurance for patients and clinicians using tirzepatide, while reinforcing the need for routine diabetic eye screening.
